ArticleThe Journal of experimental medicine1995
PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu.
Article in The Journal of experimental medicine, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 94 citations in OpenAlex.
- HO-1, RET and PML as possible markers for risk stratification of acute myelocytic leukemia and prognostic evaluation.Oncology letters · 2015Article
- Sumoylation-promoted enterovirus 71 3C degradation correlates with a reduction in viral replication and cell apoptosis.The Journal of biological chemistry · 2011Article
- The nuclear bodies inside out: PML conquers the cytoplasm.Current opinion in cell biology · 2011Review
- Regulation of apoptosis by PML and the PML-NBs.Oncogene · 2008Review
- PML interacts with Myc, and Myc target gene expression is altered in PML-null fibroblasts.Oncogene · 2005Article
- Review
- Expression of promyelocytic leukemia protein increases during the differentiation of human neuroblastoma cells.Virchows Archiv : an international journal of pathology · 2003Article
- Review
- Overexpression of promyelocytic leukemia protein precludes the dispersal of ND10 structures and has no effect on accumulation of infectious herpes simplex virus 1 or its proteins.Journal of virology · 2002Article
- Regulation of PML-dependent transcriptional repression by pRB and low penetrance pRB mutants.Oncogene · 2002Article
- Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions.Oncogene · 2002Article
- Review
- PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator.The EMBO journal · 2001Article
- The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases.Molecular and cellular biology · 2001Article
- Role of promyelocytic leukemia (PML) protein in tumor suppression.The Journal of experimental medicine · 2001Article
- A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Article
- Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor.British journal of cancer · 1999Article
- Expression and role of PML gene in normal adult hematopoiesis: functional interaction between PML and Rb proteins in erythropoiesis.Oncogene · 1999Article
- Transforming potential of the adenovirus type 5 E4orf3 protein.Journal of virology · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The chromosomal translocation t(15;17)(q22;q12) is a consistent feature of acute promyelocytic leukemia (APL) that results in the disruption of genes for the zinc finger transcription factor PML and the retinoic acid receptor alpha (RAR alpha). We have previously shown that PML is a growth suppressor and is able to suppress transformation of NIH/3T3 by activated neu oncogene. In the study presented here, the full-length PML cDNA was transfected into B104-1-1 cells (NIH/3T3 cells transformed by the activated neu oncogene) by retrovirally mediated gene transfer. We found that expression of PML could reverse phenotypes of B104-1-1 including morphology, contact-limiting properties, and growth rate in both transient-expression and stable transfectants. We also demonstrated that PML is able to suppress clonogenicity of B104-1-1 in soft agar assay and tumorigenicity in nude mice. These results strongly support our previous finding that PML is a transformation or growth suppressor. Our results further demonstrate that expression of PML in B104-1-1 cells has little effect on cell cycle distribution. Western blot analysis demonstrated that suppression of neu expression in B104-1-1 by PML was insignificant in the transient transfection experiment but significant in the PML stable transfectants. This study suggests that PML may suppress neu expression and block signaling events associated with activated neu. This study supports our hypothesis that disruption of the normal function of PML, a growth or transformation suppressor, is a critical event in APL leukomogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.